Tofacitinib: Additional Phase III data

Additional data from the double-blind, placebo-controlled Phase III ORAL Scan (1044) trial in 535 evaluable patients with moderate to severe active RA who had an inadequate response to methotrexate showed that twice-daily 5 and 10 mg oral tofacitinib plus methotrexate maintained efficacy improvements at 2 years in ACR response rates, mTSS, DAS28

Read the full 520 word article

User Sign In